Alvin J. Siteman Cancer Center

Last updated

Alvin J. Siteman
Cancer Center
Alvin J. Siteman Cancer Center
Geography
Location St. Louis, Missouri, United States
Organization
Type Specialist
Affiliated university Barnes-Jewish Hospital, Washington University School of Medicine
Services
Speciality Cancer
Public transit access Bus-logo.svg MetroBus
BSicon TRAM.svg   Red    Blue  
At Central West End station
History
Opened1999
Links
Website www.siteman.wustl.edu
Lists Hospitals in Missouri

The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). [1] Siteman is also the only area member of the National Comprehensive Cancer Network, [2] a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care. [3]

Contents

Siteman treats more than 75,000 individual patients, including 12,000 newly diagnosed patients, every year. [4]

Locations

Siteman's main facility is at Washington University Medical Center in St. Louis’ Central West End neighborhood. In 2021, work began on a new main facility on the medical campus that is scheduled for completion in summer 2024. [5] Five other St. Louis-area sites offer specialized cancer care in suburban locations:

History and leadership

In 1999, Alvin J. and Ruth Siteman committed $35 million to the development of the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. The commitment was the largest gift ever received by Barnes-Jewish and Washington University in support of cancer research, patient care and services, education and community outreach. [9]

Timothy Eberlein has been director of the center since its inception. [10] John DiPersio is deputy director. [11]

In 2001, the NCI designated Siteman as a Cancer Center, which signaled that the institution had demonstrated significant scope and quality in its cancer research programs. The designation came with $850,000 per year in federal research grants. [12] The NCI named Siteman a Comprehensive Cancer Center in 2005, recognizing its broad-based research, outreach and education activities, and awarded the center a five-year, $21 million support grant. [13] The NCI renewed the designation in 2010 and awarded another five-year grant, totaling $23 million. The grants fund programs and specialized services that promote multidisciplinary research, as well as shared scientific resources and seed awards that enable investigators to develop and pursue new research opportunities. [14]

Alvin J. Siteman announced in 2010 that he would donate $1 million annually to an endowment fund at the center to advance cancer prevention, diagnosis and treatment programs that might not receive federal funding. [15]

Patient care and services

More than 350 Washington University research scientists and physicians provide inpatient and outpatient care at Siteman. [16] The center also offers patient and family support services, including discussion and education groups. [17]

In 2018, Siteman announced it would build a second proton therapy unit at its S. Lee Kling Proton Therapy Center. The first opened in late 2013. [18]

Research

Scientists and physicians affiliated with Siteman hold more than $145 million in cancer research and related training grants. The results of basic laboratory research are rapidly incorporated into treatment advances. This process is enhanced by patient access to more than 500 therapeutic clinical studies, [19] including many collaborative efforts with other leading cancer centers throughout the country. [20]

In 2013, three scientists affiliated with Siteman, Washington University School of Medicine and the McDonnell Genome Institute were included on the Thomson Reuters list of “Hottest Scientific Researchers of 2012”: Richard K. Wilson, Elaine Mardis, and Li Ding. The list recognized the 21 most-cited researchers of 2012. Robert Fulton, a fourth scientist from Washington University School of Medicine and the McDonnell Genome Institute, also made the list. [21]

Research advances

Researchers affiliated with Siteman and/or Washington University School of Medicine have pioneered important advances in cancer research, prevention, education and treatment. Highlights and ongoing studies include these projects:

2018 — Personalized brain cancer vaccines

2017 — CAR-T cell therapy and using Zika virus to fight brain cancer

2016 — Chemotherapy for brain tumors

2015 — Melanoma vaccine and urine test for kidney cancer

2014 — Breast cancer vaccine and cancer goggles

2013 — Endometrial cancer and leukemia

2012 — Leukemia, breast cancer research and cancer prevention

2011 — Blood-related cancers

2010 — Pediatric cancers

2008 — Genetic sequencing

2007 — Nanotechnology and radiation therapy

2006 — Photoacoustic imaging

2003 — Breast cancer

2001 — Imaging and the immune system's role in controlling cancer

1998 — Biopsies

1994 — Genetic screening test for thyroid cancer

1979 — Bone marrow transplants

Mid-1970s — Imaging

1954 — Growth factors and cancer

1946 — Radiocarbon in cancer research

1941 — Cyclotron

1933 — Lung cancer surgery and the disease's link to smoking

Cancer prevention and control

Siteman and Washington University School of Medicine are actively engaged in many projects to prevent cancer in the St. Louis region and across the United States. These efforts include:

Education and community outreach

In addition to treatment and research programs, Siteman is involved with community outreach, education and screening. Efforts include:

Siteman Cancer Network

In 2017, Siteman Cancer Center launched the Siteman Cancer Network, an affiliation with regional medical centers that is aimed at improving the health of individuals and communities through cancer research, treatment and prevention. Network members are Boone Hospital Center's Stewart Cancer Center in Columbia, Missouri, [69] Phelps Health's Delbert Day Cancer Institute in Rolla, Missouri, [70] Alton Memorial Hospital in Alton, Illinois [71] and Southern Illinois Healthcare in Carbondale, Illinois. [72]

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical technology

Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when a group of cells within the brain turn cancerous and grow out of control, creating a mass. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Cancer</span> Group of diseases involving cell growth

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans.

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

<span class="mw-page-title-main">Roswell Park Comprehensive Cancer Center</span> Hospital in New York, United States

Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.

<span class="mw-page-title-main">Lloyd J. Old</span> 20th-century American immunology researcher

Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

Adoptive cell transfer (ACT) is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient. Comparatively, allogeneic therapies involve cells isolated and expanded from a donor separate from the patient receiving the cells.

Racotumomab is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

<span class="mw-page-title-main">Signs and symptoms of cancer</span> Medical condition

Cancer symptoms are changes in the body caused by the presence of cancer. They are usually caused by the effect of a cancer on the part of the body where it is growing, although the disease can cause more general symptoms such as weight loss or tiredness. There are more than 100 different types of cancer with a wide range of signs and symptoms which can manifest in different ways.

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

<span class="mw-page-title-main">Childhood cancer</span> Medical condition

Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, but it is often more complex than adult cancers with unique biological characteristics. Its research and treatment is very challenging and limited. For this reason, in countries that are low- and mid-income, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management.

University of Virginia Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center affiliated with the University of Virginia School of Medicine and the UVA Health System.

Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).

David Terry Curiel is an American cancer biologist. He is a professor of Radiation Oncology at Washington University School of Medicine and Director of the Biologic Therapeutics Center. In 1995, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding. In 2021, Curiel developed a vaccine that targets the SARS-CoV-2 virus through the nose.

Rebecca Aft is an American surgical oncologist and breast cancer researcher. Holds the inaugural title of Moley Professor of Endocrine and Oncologic Surgery at Washington University School of Medicine in St. Louis. Aft studies the mechanisms of breast cancer metastasis and explores potential targets for treatment. Her work has identified the anti-metastatic effects of bisphosphonates in patients with breast cancer. 

References

  1. VandeWater, Judith (January 4, 2005). "St. Louis cancer center achieves highest designation". St. Louis Post-Dispatch. Retrieved June 27, 2012.
  2. "NCCN Member Institutions". National Comprehensive Cancer Network. Retrieved March 27, 2012.
  3. "Siteman joins cancer center alliance". St. Louis Business Journal. March 21, 2006. Retrieved June 29, 2012.
  4. "Siteman Cancer Center earns highest NCI rating". The Cancer Letter. June 19, 2020. Retrieved July 28, 2020.
  5. Bryant, Tim (July 30, 2021). "Washington U. to open 659,000-square-foot cancer center in Central West End". St. Louis Post-Dispatch. Retrieved July 30, 2021.
  6. Rizvic, Veneta (October 22, 2019). "Siteman Cancer Center unveils opening date for $26.3M facility in Florissant". St. Louis Business Journal. Retrieved December 12, 2019.
  7. Liss, Samantha (January 2, 2013). "$27.5 million outpatient Siteman Cancer Center to open Monday". St. Louis Business Journal. Retrieved January 11, 2013.
  8. Maddox, Teri (January 13, 2020). "Siteman Cancer Center location opening in Shiloh; Swansea office complex for sale". Belleville News-Democrat. Retrieved January 16, 2020.
  9. "Couple donate $35 million for cancer research". St. Louis Post-Dispatch. November 20, 1999. Retrieved June 24, 2013.(subscription required)
  10. "Siteman Cancer Center gets $23M". St. Louis Business Journal. November 1, 2010. Retrieved March 27, 2012.
  11. "National Comprehensive Cancer Network, MD, PhD". Siteman Cancer Center. Retrieved March 29, 2012.
  12. VandeWater, Judith (August 16, 2001). "Siteman Center Here Wins Designation from National Cancer Institute". St. Louis Post-Dispatch. Retrieved June 15, 2012.
  13. VandeWater, Judith (January 4, 2005). "Siteman Cancer Center here achieves highest designation". St. Louis Post-Dispatch. Retrieved June 15, 2012.
  14. Munz, Michele (November 21, 2010). "Siteman Cancer Center designated as Comprehensive Cancer Center, gets $23 million". St. Louis Post-Dispatch. Retrieved April 13, 2012.
  15. "St. Louis philanthropist endows cancer fund". The Associated Press. January 26, 2010. Archived from the original on April 7, 2010. Retrieved June 15, 2012.
  16. "NCCN Member Institution Profile". National Comprehensive Cancer Network. Archived from the original on May 12, 2012. Retrieved March 15, 2012.
  17. "Patient & Visitor Information". Siteman Cancer Center. Retrieved May 15, 2012.
  18. "St. Louis Medical Organizations Plan More Proton Therapy". U.S. News & World Report. Retrieved December 10, 2018.
  19. "Find A Clinical Trial". Siteman Cancer Center. Retrieved October 15, 2017.
  20. "About Siteman". Siteman Cancer Center. Retrieved October 27, 2017.
  21. "Who and What Was Hot in Scientific Research in 2012" . Retrieved June 5, 2013.
  22. Berson, Scott (May 30, 2018). "Scientists created a brain-cancer vaccine - and so far it's 'remarkably promising'". The McClatchy Company/Miami Herald. Retrieved August 14, 2018.
  23. Bernhard, Blythe (August 19, 2017). "New treatment for deadly blood cancers expected to be approved soon". St. Louis Post-Dispatch. Retrieved October 3, 2017.
  24. McGinley, Laurie (October 18, 2017). "Cutting-edge immunotherapy treatment approved for another deadly cancer". The Washington Post. Retrieved October 25, 2017.
  25. Roberts, Michelle (September 5, 2017). "Zika virus used to treat aggressive brain cancer". St. Louis Post-Dispatch. Retrieved October 3, 2017.
  26. Gruber, Ben (May 4, 2016). "Laser brain cancer treatment may bring extra advantage". Reuters. Retrieved May 13, 2016.
  27. Norton, Amy (April 2, 2015). "Experimental Melanoma Vaccine Shows Early Promise". HealthDay. Retrieved September 14, 2015.
  28. "Urine Test Shows Promise for Early Diagnosis of Kidney Cancer". HealthDay. March 20, 2015. Retrieved September 14, 2015.
  29. Mahesh, Roshni (December 2, 2014). "Vaccine to Slow Down Metastatic Breast Cancer". International Business Times. Retrieved September 14, 2015.
  30. Mintz, Joe (February 11, 2014). "New Glasses Makes Sure 'No Cancer Is Left Behind,' Causes Malignant Cells To Glow Blue". International Business Times. Retrieved September 14, 2015.
  31. Winslow, Ron (May 1, 2013). "Genomic Studies Unlock Details on Two Cancers". The Wall Street Journal. Retrieved May 1, 2013.
  32. Kolata, Gina (July 7, 2012). "In Treatment for Leukemia, Glimpses of the Future". The New York Times. Retrieved July 20, 2012. "Frontiers in Cancer Research". Charlie Rose. New York. July 17, 2012. 28 minutes in. PBS. Archived from the original on July 21, 2012. Retrieved July 20, 2012.
  33. "Gene therapy: Genetic mutations predict which cancers will respond to treatment". The Economist. June 16, 2012. Retrieved June 16, 2012.
  34. "In Nurses' Lives, a Treasure Trove of Health Data". The New York Times. September 15, 1998. Retrieved June 29, 2012.
  35. Dohney, Kathleen (April 9, 2011). "Teen Drinking May Boost Odds of Precancerous Breast Changes". HealthDay News and U.S. News & World Report. Retrieved April 16, 2012.
  36. Harmon, Katherine (March 28, 2011). "U.S. Cancer Rates Could Be Cut in Half Today Based on What's Already Known". Scientific American. Retrieved April 16, 2012.
  37. Harmon, Katherine (March 2012). "U.S. Cancer Rates Could Be Cut in Half Today Based on What's Already Known". Scientific American. Retrieved April 6, 2012.
  38. Gamble, Molly (January 18, 2012). "70 Hospitals and Health Systems With Great Oncology Programs". Becker’s Hospital Review. Retrieved June 20, 2012.
  39. Szabo, Liz (January 26, 2010). "Genetic study targets cancer in kids". USA Today. Retrieved June 20, 2012.
  40. Grady, Denise (November 6, 2008). "Experts Decode Cancer Patient's Genes, Seeking Treatment Clues". The New York Times. Retrieved July 20, 2012.
  41. "Nanoparticles used to track cells". UPI. July 27, 2007. Retrieved July 25, 2012.
  42. Melcer, Rachel (July 27, 2007). "Innovating with Daniel Low". St. Louis Post-Dispatch. St. Louis. pp. B4.
  43. Lihong Wang, Ph.D. (April 30, 2012). New technique brings cancer screening into sharper focus (Web news). St. Louis: Reuters. Retrieved June 25, 2012.ß
  44. "Breast cancer vaccine ready for tests soon". The Daily Telegraph. March 10, 2005. Archived from the original on February 6, 2012. Retrieved June 15, 2012.
  45. Hesman, Tina (June 15, 2001). "Scan test may aid choice for breast cancer therapy". St. Louis Post-Dispatch. St. Louis. pp. C5.
  46. Siegel, Judy (April 29, 2001). "Immune system shown to prevent and shape cancer susceptibility". The Jerusalem Post. Jerusalem. p. 4.
  47. Derbyshire, David (November 21, 2007). "Living your entire life with cancer – Keeping disease dormant". The Daily Telegraph. Surry Hills, Australia. p. 25.
  48. "Cancer Care Tied to Genetic Makeup". The Toronto Star. March 26, 2001. pp. A06.
  49. "First magnet-controlled brain surgery performed". BBC News. December 23, 1998. Retrieved April 13, 2012.
  50. Signor, Roger (June 29, 1994). "WU Surgeons Remove Gland, Cancer Threat". St. Louis Post-Dispatch. St. Louis, Missouri. pp. 1A.
  51. "Leukemia Victims Get Own Marrow In Transplants". The Washington Post. Washington, D.C. August 24, 1979. pp. A9.
  52. Saxon, Wolfgang (June 21, 1996). "Michel M. Ter-Pogossian, 71; Led Research on PET Scanner". The New York Times. Retrieved April 4, 2012.Ter-Pogossian, M.M.; Phelps, M.E.; Hoffman, E.J.; Mullani, N.A. (January 1975). "A positron-emission transaxial tomograph for nuclear imaging (PETT)". Radiology. 114 (1). Philadelphia, Pa.: Radiological Society of North America: 89–98. doi:10.1148/114.1.89. ISSN   0033-8419. PMID   1208874.
  53. "The New Nobels". Newsweek. October 27, 1986. p. 111.
  54. Tilyou, Sarah M. (May 1989). "History of Nuclear Medicine in St. Louis: A City of Nuclear Medicine Landmarks and Innovators". The Journal of Nuclear Medicine. 30 (5). Reston, Va.: Society of Nuclear Medicine: 569–579. ISSN   0161-5505 . Retrieved April 13, 2012.
  55. Tilyou, Sarah M. (May 1989). "History of Nuclear Medicine in St. Louis: A City of Nuclear Medicine Landmarks and Innovators". The Journal of Nuclear Medicine. 30 (5). Reston, Va.: Society of Nuclear Medicine: 569–579. ISSN   0161-5505 . Retrieved April 13, 2012.
  56. "Medicine: Death of a Surgeon". Time. March 18, 1957. Archived from the original on September 30, 2007. Retrieved April 6, 2012.
  57. White, Larry C. (June 1988) [1988], Merchants of Death: The American Tobacco Industry (1 ed.), Beech Tree Books, ISBN   978-0688067069
  58. "Health Scan: Scientists learn how colon cancer spreads". The Jerusalem Post. September 23, 2007. Retrieved June 15, 2012.
  59. "Zuum – Health Tracker". iTunes . Retrieved June 26, 2012.
  60. "TOGETHER - Every Woman's Guide to Preventing Breast Cancer". iTunes . Retrieved September 14, 2015.
  61. Wittenauer, Cheryl (September 24, 2008). "Mo. Blacks closing racial gap in new cancer cases". The Associated Press. St. Louis. Retrieved June 26, 2012.
  62. Jackson Jr., Harry (August 23, 2004). "Black St. Louisans get healthy at church". St. Louis Post-Dispatch. Retrieved June 24, 2013.(subscription required)
  63. Sheridan, Kerry (March 28, 2012). "Half of all cancers are preventable: study". Agence France Presse. Washington, D.C. Archived from the original on January 25, 2013. Retrieved June 26, 2012.
  64. Gregorian, Cynthia Billhartz (October 27, 2010). "Researchers target cancer screenings among blacks". St. Louis Post-Dispatch. Retrieved July 20, 2012.
  65. Jackson Jr., Harry (August 23, 2004). "Black St. Louisans get healthy at church". St. Louis Post-Dispatch. Retrieved June 24, 2013.(subscription required)
  66. Kreuter, Matthew W.; Alcaraz, Kassandra I.; Pfeiffer, Debra; Christopher, Kara (March–April 2008). "Using Dissemination Research to Identify Optimal Community Settings for Tailored Breast Cancer Information Kiosks". Journal of Public Health Management and Practice. 14 (2). Lippincott Williams & Wilkins, Inc.: 160–169. doi:10.1097/01.PHH.0000311895.57831.02. PMID   18287923.
  67. "Charity Race Raised More Than $500,000 to Fight Breast Cancer". St. Louis Post-Dispatch. October 28, 2000. Retrieved June 24, 2013.
  68. "Mammography Van". Siteman Cancer Center. Retrieved April 6, 2012.
  69. Jackson Jr., Jodie (March 4, 2017). "Stewart Cancer Center joins new Siteman network". Columbia Daily Tribune. Retrieved August 14, 2018.
  70. Amos, Lori (June 26, 2018). "PCRMC advancing treatment in the community". Rolla Daily News. Retrieved August 14, 2018.
  71. Robbins, Brian (May 2, 2019). "Siteman continues push into Illinois as Alton hospital joins cancer-treatment network". St. Louis Business Journal. Retrieved May 17, 2019.
  72. Halstead, Marilyn (December 9, 2020). "Southern Illinois Healthcare is now a Siteman Cancer Network affiliate". The Southern Illinoisan. Retrieved July 30, 2021.